We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-1.57%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.49B
AUM Growth
-$396M
(-5.7%)
Cap. Flow
-$220M
Cap. Flow
% of AUM
-3.39%
Top 10 Holdings %
Top 10 Hldgs %
43.16%
Holding
163
New
23
Increased
16
Reduced
43
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LIAN
LianBio American Depositary Shares
LIAN
|
+$643M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$97.4M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$50.7M |
| 4 |
ISO
IsoPlexis Corporation Common Stock
ISO
|
+$45.4M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
+$33.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$79.2M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
+$50.6M |
| 3 |
Beam Therapeutics
BEAM
|
+$46.8M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$37.7M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$30M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.98% |
| 2 | Miscellaneous | 13.04% |
| 3 | Financials | 0.8% |
| 4 | Industrials | 0.09% |
| 5 | Consumer Staples | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCAB
76
DELISTED
BIOATLA INC
BCAB
| $13M | 0.2% |
13,224
-3,777
| -22% | -$4.83M |
|
77
Immunocore
IMCR
$1.64B
| $12.3M | 0.19% |
360,000
-40,000
| -10% | -$1.45M |
|
78
Biogen
BIIB
$31.9B
| $11.7M | 0.18% |
48,600
| – | – |
|
79
Absci
ABSI
$1.36B
| $11.6M | 0.18% |
1,411,776
-65,000
| -4% | -$740K |
|
80
Aclaris Therapeutics
ACRS
$814M
| $11.4M | 0.18% |
781,236
| – | – |
|
81
GeneDx Holdings
WGS
$2.82B
| $11.2M | 0.17% |
75,758
| – | – |
|
|
MRUS
82
DELISTED
Merus
MRUS
| $11.1M | 0.17% |
+350,000
| New | +$9.89M |
|
83
Immuneering
IMRX
$287M
| $11M | 0.17% |
681,051
| – | – |
|
84
Hyperfine
HYPR
$85M
| $10.9M | 0.17% |
+1,500,000
| New | +$11.9M |
|
|
LENZ
85
LENZ Therapeutics
LENZ
$133M
| $10.6M | 0.16% |
121,442
-3,571
| -3% | -$296K |
|
|
AGRX
86
DELISTED
Agile Therapeutics
AGRX
| $10.4M | 0.16% |
10,647
+2,687
| +34% | +$3.79M |
|
87
Harmony Biosciences
HRMY
$2.46B
| $10.2M | 0.16% |
239,258
-252,074
| -51% | -$10M |
|
|
SMIHU
88
DELISTED
Summit Healthcare Acquisition Corp. Units
SMIHU
| $9.95M | 0.15% |
1,000,000
| – | – |
|
89
Adaptive Biotechnologies
ADPT
$4.26B
| $9.9M | 0.15% |
352,804
| – | – |
|
90
Kymera Therapeutics
KYMR
$9.41B
| $9.84M | 0.15% |
155,000
-25,000
| -14% | -$1.46M |
|
|
BLSA
91
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $9.8M | 0.15% |
1,000,000
| – | – |
|
|
RACB
92
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $9.77M | 0.15% |
1,000,000
| – | – |
|
93
Tyra Biosciences
TYRA
$1.52B
| $9.47M | 0.15% |
673,352
-314,148
| -32% | -$6.24M |
|
|
DAWN
94
DELISTED
Day One Biopharmaceuticals
DAWN
| $9.37M | 0.14% |
556,047
| – | – |
|
|
ONEM
95
DELISTED
1Life Healthcare
ONEM
| $9.35M | 0.14% |
532,350
| – | – |
|
96
Celldex Therapeutics
CLDX
$3.02B
| $8.88M | 0.14% |
229,807
-163,806
| -42% | -$7.14M |
|
97
Legend Biotech
LEGN
$3.44B
| $8.81M | 0.14% |
+189,100
| New | +$9.59M |
|
|
NBTX
98
Nanobiotix
NBTX
$1.79B
| $8.58M | 0.13% |
1,059,800
| – | – |
|
|
EQRX
99
DELISTED
EQRx, Inc. Common Stock
EQRX
| $8.53M | 0.13% |
+1,250,000
| New | +$11.8M |
|
100
Madrigal Pharmaceuticals
MDGL
$12.1B
| $7.32M | 0.11% |
+86,400
| New | +$7.1M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, Perceptive Advisors held 163 positions worth $6.49B, down 5.7% from $6.88B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Perceptive Advisors withdrew a net $220M in Q4 2021, closing 16 positions and reducing 43 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $79.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in LianBio American Depositary Shares worth $347M.
- Perceptive Advisors's largest Q4 2021 buy was LianBio American Depositary Shares: 56,319,960 shares worth $347M.
- Perceptive Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $32.9M increase.
- Perceptive Advisors's biggest Q4 2021 reduction was Invitae Corporation, cutting an estimated $50.6M.
- Perceptive Advisors fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $79.2M.
- Perceptive Advisors's ten largest holdings make up 43% of its $6.49B portfolio in Q4 2021.
- Perceptive Advisors opened 23 new positions and closed 16 in Q4 2021.
- Perceptive Advisors's portfolio value fell 5.7% quarter-over-quarter to $6.49B.
Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.